Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants
ContributorsBuller, Harry R.; Halperin, J L.; Bounameaux, Henri; Prins, M.
Published inJournal of thrombosis and haemostasis, vol. 6, no. 2, p. 227-229
Publication date2008
Keywords
- Anticoagulants/standards/therapeutic use
- Bias (Epidemiology)
- Case Management
- Clinical Trials, Phase III as Topic/methods/standards
- Cost-Benefit Analysis
- Double-Blind Method
- Fibrinolytic Agents/standards/therapeutic use
- Heparin/therapeutic use
- Heparin, Low-Molecular-Weight/therapeutic use
- Humans
- Patient Selection
- Professional Practice
- Prothrombin Time/instrumentation
- Quality of Life
- Randomized Controlled Trials as Topic/methods/standards
- Thrombophilia/drug therapy
- Treatment Outcome
- Vitamin K/antagonists & inhibitors
Affiliation entities
Citation (ISO format)
BULLER, Harry R. et al. Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants. In: Journal of thrombosis and haemostasis, 2008, vol. 6, n° 2, p. 227–229. doi: 10.1111/j.1538-7836.2007.02848.x
Main files (1)
Article (Accepted version)
Identifiers
- PID : unige:1856
- DOI : 10.1111/j.1538-7836.2007.02848.x
- PMID : 18034770
Journal ISSN1538-7836
